Sunday, July 3, 2011
Saturday, July 2, 2011
New and effective diabetes drug seeking approval
We know that, Dapagliflozin is an experimental drug being studied by Bristol-Myers Squibb in partnership with AstraZeneca as a potential treatment for type 1 and 2 diabetes. Although dapagliflozin's method of action would operate on either type of diabetes or other conditions resulting in hyperglycemia, the current clinical trials specifically exclude participants with Type 1 diabetes.Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucosereabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.
New and effective diabetes drug seeking approval
New and effective diabetes drug seeking approval
Friday, July 1, 2011
Wednesday, June 29, 2011
Wednesday, June 22, 2011
Tuesday, June 21, 2011
Sunday, June 19, 2011
Thursday, June 16, 2011
Liraglutide as Additional Treatment in Type 1 Diabetes
In continuation of my update on Liraglutide...
Results of a small, observational study conducted at the University at Buffalo suggest that liraglutide (below structure) , an injectable medication used to treat type 2 diabetes, also helps type 1 diabetics on insulin achieve optimal control of their blood glucose levels.
More....
Tuesday, June 14, 2011
New drug more effective than standard treatment to prevent heart-attack deaths
In continuation of my update on ticagrelor .....
Robert Storey, Professor of Cardiology at the University of Sheffield's Department of Cardiovascular Science, presented findings today that confirm one in five deaths in the year following a heart attack could be prevented if a new drug, ticagrelor (see structure), was used instead of the standard treatment, clopidogrel...
More...
Labels:
Heart attack,
Ticagrelor (Brilinta)
Wednesday, June 8, 2011
Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma
We know that, PLX-4032(RG7204, Vemurafenib) is a highly selective inhibitor of BRAF kinase activity, with an IC50 of 44 nmol/L against V600E-mutant BRAF. BRAFV600E cancer-causing mutation occurs in most melanomas and about eight percent of all solid tumors....
More....
Labels:
Anticancer,
BRAF kinase activity,
RG7204,
vemurafenib
Tuesday, June 7, 2011
Formoterol drug improves fat burning and protein metabolism in men
We know that, Formoterol or eformoterol is a long-acting β2-agonist used in the management of asthma and/or chronic obstructive pulmonary disease (COPD). It is marketed in four forms: a dry-powder inhaler (DPI), a metered-dose inhaler (MDI), an oral tablet, and an inhalation solution, under various trade names including Foradil/Foradile (Schering-Plough in the U.S., Novartis rest of world), Oxeze (AstraZeneca), Atock (Astellas), Atimos Modulite (Trinity-Chiesi), and Perforomist (Dey).
Now researchers lead by Dr. Paul Lee of Garvan Institute of Medical Research in Sydney, have for the first time reports that research in animals has shown that formoterol can stimulate the growth of muscle and the burning of fat...
Formoterol drug improves fat burning and protein metabolism in men
Labels:
anti-obesity,
Asthma,
formoterol
Friday, June 3, 2011
Lyxumia®, as an add-on to basal Insulin, shows significant positive phase III results
Sanofi announced today that new results from a Phase III study showed that the investigational product Lyxumia® (lixisenatide see structure above), when used as an add-on therapy to basal insulin (in association with or without metformin), achieved its primary efficacy endpoint of significantly reducing HbA1c versus placebo for patientswith type 2 diabetes without significantly increasing their risk of hypoglycemia...
More...
Labels:
Diabetes,
Insulin,
Lyxumia® (lixisenatide)
Wednesday, June 1, 2011
Airtel: Switch off Diesel
Hi ,
I just signed a petition opposing Airtel's use of dirty diesel energy to power their cell phone towers.
Please read the mail below and take action.
Regards,
Dear friends,
Thanks to the telecommunications sector, every new call and SMS is hurting our environment. Lakhs of massive mobile network towers in our country run on dirty diesel.
Airtel is the market leader and trend-setter of the Indian telecom industry. If we get them to switch to renewable energy, it will set an example for the others to follow. Customers are the mainstay of this industry. Airtel would notice if customers ask them to make their calls green by using clean energy to power company’s mobile towers.
You should ask Airtel to switch to renewable energy.
http://www.greenpeace.org/india/en/What-We-Do/Stop-Climate-Change/Green-Electronics/switch-off-diesel/airtel-switch-off-diesel/
Several current and potential Airtel subscribers, asking them to switch to renewable energy will help put pressure on them to act. Since the company is bound to provide good service to its subscribers, they will not be able to ignore this feedback.
Like coal and nuclear, oil too is an unsustainable energy option. The Deepwater Horizon oil spill last year showed the dangers of our addiction to oil.[2] Studies conducted by the Intergovernmental Panel on Climate Change have shown that renewable energy is capable of powering the world.[3] Airtel needs to realise this and quit dirty energy.
Tell them now.
http://www.greenpeace.org/india/en/What-We-Do/Stop-Climate-Change/Green-Electronics/switch-off-diesel/airtel-switch-off-diesel/
Thanks a billion!
Abhishek Pratap
Climate and Energy Campaigner
Greenpeace India
Sources:
1. Dirty Talking? Case for telecom to shift from diesel to renewable, Greenpeace India, May 19, 2011
http://www.greenpeace.org/india/Global/india/docs/cool-it/reports/telecom-report-may-2011.pdf [PDF]
2. BP Oil Spill: How Bad Is Damage to Gulf One Year Later? Time magazine, April 19, 2011
http://news.yahoo.com/s/time/20110419/hl_time/08599206603100
3. Renewable energy can power the world, says landmark IPCC study, Guardian, May 9, 2011
http://www.guardian.co.uk/environment/2011/may/09/ipcc-renewable-energy-power-worlddr.umesh1969@gmail.com
You are receiving this email because someone you know sent it to you from the Greenpeace site. Greenpeace retains no information about individuals contacted through its site, and will not send you further messages without your consent -- although your friends could, of course, send you another message.
New drugs (Victrelis and Incivek ) encouraging for African Americans with hepatitis C
Current standard of treatment of interferon and ribavirun has only been effective in curing 38 to 40 percent of patients with chronic hepatitis C genotype 1. In clinical trials, Victrelis and Incivek, when working in concert with interferon and ribavirun, cured 65 to 75 percent of people with chronic disease and Victrelis-alone doubled the previous cure rate among African Americans......
Victrelis (Boceprevir)
Incivek (Telaprevir)
News Release Archives > New drugs encouraging for African Americans with hepatitis C
Subscribe to:
Posts (Atom)